Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients

  1. He S. Yang
  2. Sabrina E. Racine-Brzostek
  3. Mohsen Karbaschi
  4. Jim Yee
  5. Alicia Dillard
  6. Peter A.D. Steel
  7. William T. Lee
  8. Kathleen A. McDonough
  9. Yuqing Qiu
  10. Thomas J. Ketas
  11. Erik Francomano
  12. P.J. Klasse
  13. Layla Hatem
  14. Lars Westblade
  15. Heng Wu
  16. Haode Chen
  17. Robert Zuk
  18. Hong Tan
  19. Roxanne C. Girardin
  20. Alan P. Dupuis
  21. Anne F. Payne
  22. John P. Moore
  23. Melissa M. Cushing
  24. Amy Chadburn
  25. Zhen Zhao

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.bios.2021.113008
  2. ScreenIT

    SciScore for 10.1101/2020.11.19.20235044: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Sources of serum specimens and data acquisition: The clinical study was approved by the Institutional Review Board (#20-03021671) of Weill Cornell Medicine (WCM) with a waiver of informed consent.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Details are described in the Supplemental Materials. 2.2. Testing-on-a-probe (TOP) SARS-CoV-2 total RBD antibody assay (TAb): The TOP-TAb assay measures the overall binding between SARS-CoV-2 antibodies and the receptor-binding domain (RBD) of the virus spike (S) protein (Figure 1A).
    SARS-CoV-2 total RBD
    suggested: None
    2 surrogate neutralizing antibody assay (SNAb): Designed as a competitive binding assay, the TOP-SNAb (Figure 1B), is based on the anti-SARS-CoV-2 antibody-mediated inhibition of the interaction between the ACE2 receptor protein and the RBD.
    anti-SARS-CoV-2
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    The plaque reduction neutralization test (PRNT) and pseudo virus neutralization test (PsV): The PRNT assay detects viral specific antibodies based on their ability to neutralize their cognate viral infections in Vero E6 cells (C1008, ATCC CRL-1586)(Lee WT 2020).
    Vero E6
    suggested: None
    Software and Algorithms
    SentencesResources
    The TAb assay is fully automated on the Pylon 3D analyzer (ET Healthcare).
    ET Healthcare
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.11.19.20235044v1 on medRxiv